Yuxiang Xie

Yuxiang Xie

Auto-generated profile, based on publicly available information

Yuxiang Xie

Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20057, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2018 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
XCXiu-Tang Cheng
Xiu-Tang Cheng
YXYu-Xiang Xie
Yu-Xiang Xie
BZBing Zhou
Bing Zhou
NHNing Huang
Ning Huang
TFTamar Farfel-Becker
Tamar Farfel-Becker
ZSZu-Hang Sheng
Zu-Hang Sheng
Despite widespread distribution of LAMP1 and the heterogeneous nature of LAMP1-labeled compartments, LAMP1 is routinely used as a lysosomal marker, and LAMP1-positive organelles are often referred to as lysosomes. In this study, we use immunoelectron microscopy and confocal imaging to provide quantitative analysis of LAMP1 distribution in various autophagic and endolysosomal organelles in neurons. Our study demonstrates that a significant portion of LAMP1-labeled organelles do not contain detectable lysosomal hydrolases including cathepsins D and B and glucocerebrosidase. A bovine serum albumin–gold pulse–chase assay followed by ultrastructural analysis suggests a heterogeneity of degradative capacity in LAMP1-labeled endolysosomal organelles. Gradient fractionation displays differential distribution patterns of LAMP1/2 and cathepsins D/B in neurons. We further reveal that LAMP1 intensity in familial amyotrophic lateral sclerosis–linked motor neurons does not necessarily reflect lysosomal deficits in vivo. Our study suggests that labeling a set of lysosomal hydrolases combined with various endolysosomal markers would be more accurate than simply relying on LAMP1/2 staining to assess neuronal lysosome distribution, trafficking, and functionality under physiological and pathological conditions.

3 November 2010 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
YXYuxiang Xie
Yuxiang Xie
MHMichael R. Hayden
Michael R. Hayden
BXBaoji Xu
Baoji Xu
Huntington's disease (HD) is caused by an expansion of the polyglutamine tract at the N terminus of huntingtin. This mutation reduces levels of BDNF in the striatum, likely by inhibiting corticalBdnfgene expression and anterograde transport of BDNF from the cerebral cortex to the striatum. Substantial evidence suggests that this reduction of striatal BDNF plays a crucial role in HD pathogenesis. Here we report that overexpression of BDNF in the forebrain rescues many disease phenotypes in YAC128 mice that express a full-length human huntingtin mutant with a 128-glutamine tract. TheBdnftransgene, under the control of the promoter for α subunit of Ca2+/calmodulin-dependent protein kinase II, greatly increased BDNF levels in the cerebral cortex and striatum. BDNF overexpression in YAC128 mice prevented loss and atrophy of striatal neurons and motor dysfunction, normalized expression of the striatal dopamine receptor D2 and enkephalin, and improved procedural learning. Furthermore, quantitative analyses of Golgi-impregnated neurons revealed a decreased spine density and abnormal spine morphology in striatal neurons of YAC128 mice, which was also reversed by increasing BDNF levels in the striatum. These results demonstrate that reduced striatal BDNF plays a crucial role in the HD pathogenesis and suggest that attempts to restore striatal BDNF level may have therapeutic effects to the disease.

9 September 2021 in Neuron
Verified
Journal Article
Closed access
KCKelly A. Chamberlain
Kelly A. Chamberlain
NHNing Huang
Ning Huang
YXYuxiang Xie
Yuxiang Xie
FLFrancesca LiCausi
Francesca LiCausi
SLSunan Li
Sunan Li
ZSZu-Hang Sheng
Zu-Hang Sheng

23 July 2018 in Autophagy
Verified
Journal Article
Closed access
XCXiu-Tang Cheng
Xiu-Tang Cheng
YXYu-Xiang Xie
Yu-Xiang Xie
BZBing Zhou
Bing Zhou
NHNing Huang
Ning Huang
TFTamar Farfel-Becker
Tamar Farfel-Becker
ZSZu-Hang Sheng
Zu-Hang Sheng
Lysosomes serve as the degradation hubs for macroautophagic/autophagic and endocytic components, thus maintaining cellular homeostasis essential for neuronal survival and function. LAMP1 (lysosomal associated membrane protein 1) and LAMP2 are distributed among autophagic and endolysosomal organelles. Despite widespread distribution, LAMP1 is routinely used as a lysosome marker and LAMP1-positive organelles are often referred to as lysosomal compartments. By applying immuno-electron microscopy (iTEM) and confocal imaging combined with Airyscan microscopy, we expand on the limited literature to provide a comprehensive and quantitative analysis of LAMP1 distribution in various autophagic and endolysosomal organelles in neurons. Our study demonstrates that a significant portion of LAMP1-labeled organelles lack major lysosomal hydrolases. BSA-gold pulse-chase assay further shows heterogeneous degradative capacities of LAMP1-labled organelles. In addition, LAMP1 intensity is not a sensitive readout to assess lysosomal deficits in familial amyotrophic lateral sclerosis-linked motor neurons in vivo. Our study thus calls for caution when interpreting LAMP1-labeled organelles in the nervous system where LAMP1 intensity, trafficking, and distribution do not necessarily represent degradative lysosomes or autolysosomes under physiological and pathological conditions. ALS: amyotrophic lateral sclerosis; BSA: bovine serum albumin; DRG: dorsal root ganglion; IGF2R/CI-M6PR: insulin like growth factor 2 receptor; iTEM: immuno-transmission electron microscopy; LAMP1/2: lysosomal associated membrane protein 1/2; P80: postnatal day 80; sMNs: spinal motor neurons.

1 May 2017 in Neuron
Verified
Journal Article
Closed access
MLMei-Yao Lin
Mei-Yao Lin
XCXiu-Tang Cheng
Xiu-Tang Cheng
PTPrasad Tammineni
Prasad Tammineni
YXYuxiang Xie
Yuxiang Xie
BZBing Zhou
Bing Zhou
ZSZu-Hang Sheng
Zu-Hang Sheng

19 November 2007 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
KGKusumika Gharami
Kusumika Gharami
YXYuxiang Xie
Yuxiang Xie
JAJuan Ji An
Juan Ji An
STSusumu Tonegawa
Susumu Tonegawa
BXBaoji Xu
Baoji Xu
Huntington’s disease (HD), a dominantly inherited neurodegenerative disorder characterized by relatively selective degeneration of striatal neurons, is caused by an expanded polyglutamine tract of the huntingtin (htt) protein. The htt mutation reduces levels of brain‐derived neurotrophic factor (BDNF) in the striatum, likely by inhibiting cortical BDNF gene expression and anterograde transport of BDNF from cortex to striatum. However, roles of the BDNF reduction in HD pathogenesis have not been established conclusively. We reasoned that increasing striatal BDNF through over‐expression would slow progression of the disease if BDNF reduction plays a pivotal role in HD pathogenesis. We employed a Bdnf transgene driven by the promoter for the alpha subunit of Ca2+/calmodulin‐dependent kinase II to over‐express BDNF in the forebrain of R6/1 mice which express a fragment of mutant htt with a 116‐glutamine tract. The Bdnf transgene increased BDNF levels and TrkB signaling activity in the striatum, ameliorated motor dysfunction, and reversed brain weight loss in R6/1 mice. Furthermore, it normalized DARPP‐32 expression of the 32 kDa dopamine and cAMP‐regulated phosphoprotein, increased the number of enkephalin‐containing boutons, and reduced formation of neuronal intranuclear inclusions in the striatum of R6/1 mice. These results demonstrate crucial roles of reduced striatal BDNF in HD pathogenesis and suggest potential therapeutic values of BDNF to HD.